UNITED NEWS INTERNATIONAL (UNI) — The U.S. Food and Drug Administration approved the first drug designed to prevent migraines on May 17. 

It’s called Aimovig.

It’s designed by Amgen Inc. and Novartis AG.

Aimovig works by blocking the activity of a molecule involved in migraine attacks.

Users would receive injections of Aimovig once a month, every month, under their skin.

In clinical trials, patients had, on average, the number of migraines they experienced each month cut in half.

Others stopped having migraines entirely.

According to The Associated Press, the drug will cost patients $6,900 a year without insurance.

The AP reports several other migraine-preventing treatments are in the works, including three shots that are expected to be approved by next year.

An official with the FDA’s Center for Drug Evaluation and Research hailed the approval of Aimovig as a new way to treat a “painful and often debilitating condition.”